Conference Presentation

Gaining Momentum Across End Markets Corporate Initiatives Tobacco Milestones Hemp/Cannabis Milestones 2018 Pursued opportunity from the FDA's Advance Notice of Proposed Rulemaking (ANPRM) to reduce nicotine in cigarettes Premarket Tobacco Product Application (PMTA) submitted to the FDA seeking authorization to commercialize reduced nicotine content tobacco cigarettes Modified Risk Tobacco Product Application (MRTPA) submitted to the FDA for authorization to market VLNⓇ reduced nicotine content cigarettes with pack and advertising claims | 2019 Expanded R&D capabilities into adjacent hemp/cannabis applications The FDA applications for VLNⓇ cigarettes advanced with completion of the FDA's inspection of manufacturing facility The FDA accepted and filed for substantive scientific review MRTPA The FDA determined that sale of 22nd Century's proprietary reduced nicotine content cigarettes is 'appropriate for the protection of public health' Worldwide and exclusive strategic R&D partnership formed with KeyGene Initial investment in Panacea Life Sciences, Inc., a hemp CBD company * 2020+ 22nd Century Group, Inc. Further strengthened the executive leadership team with the addition of James A. Mish, CEO and John Franzino, CFO bringing deep industry experience The FDA's Tobacco Products Scientific Advisory Committee (TPSAC) reviewed MRTPA MRTPA public comment period closed Prepare and execute VLNⓇ commercial launch Advanced non-GMO plant lines and product development Announced high-quality genome sequence assembly with KeyGene of two hemp/cannabis lines and established new, proprietary bioinformatics platform 16

View entire presentation